Guggenheim Upgrades Sensei Biotherapeutics (NASDAQ:FTH) to “Strong-Buy”

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

A number of other research firms have also recently weighed in on FTH. Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. Citigroup began coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price target for the company. Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Down 3.2%

Shares of Sensei Biotherapeutics stock opened at $34.24 on Tuesday. The stock has a market cap of $884.76 million, a PE ratio of -0.24 and a beta of -0.28. The business has a 50 day moving average of $31.94. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. Equities analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Insider Buying and Selling at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh bought 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were acquired at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 49,494 shares of company stock worth $1,188,822 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FTH. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the first quarter worth approximately $22,758,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.